Clinicodemographic Profile of Metastatic Prostate Cancer Patients in a Tertiary Care Centre
Abstract
Aim of the study: was to examine the clinical and
treatment features of patients presenting with metastatic
prostate cancer in our tertiary care centre. Material: Data
was collected retrospectively over a 5 year period from
tumor registry records. Results: Majority of patients were
symptomatic upfront with bone metastasis commonly at
presentation. Median PSA at presentation was 155.5 ng/
ml. Overall median time to progression was 10 months.
Site of metastasis, PSA value, Gleason grade and mode of
treatment were not adverse prognostic factors.
Conclusion: Clinical, pathological and treatment factors
did not predict a decreased time to progression. Hence,
molecular markers can be tried to predict survival
outcomes. No difference with respect to medical and
surgical castration and progression to CRPC.
Full Text:
PDFReferences
http://nrcpindia.ORG/ALL_NRCP_REPORTS/
PBCR_REPORT_ 2012_2014/
Gronberg , H. Prostate Cancer Epidemiology. The Lancet
; 361 (9360): 859-864.
Bubendorf, L.; Schopfer, A.; Wagner, U.; Sauter, G.;
Moch, H.; Willi, N.; Gasser, T.C.; Mihatsch M. J. Metastatic
patterns of prostate cancer: An autopsy study of 1,489
patients. hum. patrol, 2000,31,578-583.
Weight CJ, Klein EA, Jones JS. Androgen deprivation falls
as orchidectomy rated rise after changes in reimbursement
in US medicare population. Cancer. 2008; 112 (10): 2106-7.
Chon J K , Jacobs S C, Naslund M J. The cost of medical
versus surgical hormonal therapy for metastatic prostate
cancer. The journal of Urology, 2000,164 (3) : 735-737.
Botto H, Roupret M, Mathieu F, Richard F. Multicentre
randomized trial comparing triptorelin medical castration
versus surgical castration in the treatment of locally
advanced or metastatic prostate cancer. Progress en
Urologie, 2007, 17(2):235-239.
Denis L, Murphy GP. overview of prostate phase III trials
on combined androgen treatment in patients with metastatic
prostate cancer. Cancer 1993; 72:3888-3895.
Gandaglia G et al. Impact of the site of metastasis on
survival in patients with metastatic prostate cancer. Eur Urol
, http://dx.doi.org/10.1016/j.euroro.2014.07.020.
Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi
M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK.
Efficacy of androgen deprivation therapy (ADT) in patients
with advanced prostate cancer: association between Gleason
score, prostate-specific antigen level, and prior ADT
exposure with duration of ADT effect. Cancer. 2008;112
(6):1247–1253.
Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L,
Raventos CX, Orsola A, Planas J, Catalan R, Reventos J.
Usefulness of prostate-specific antigen nadir as predictor of
androgen-indepen- dent progression of metastatic prostate
cancer. Int J Biol Markers. 2005;20(4):209–216.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
An Initiative of The Tamil Nadu Dr MGR Medical University